Parp Inhibitors

Olaparib Phase 3 Development Discontinued by AstraZeneca

(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: “The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a …

Olaparib Phase 3 Development Discontinued by AstraZenecaRead More »

Clovis to Develop Pfizer’s PARP Inhibitor

Clovis Oncology will develop Pfizer’s PF-01367338 PARP Inhibitor under a development and licensing agreement announced today worth $255 million. Pfizer’s oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338 is currently  in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis …

Clovis to Develop Pfizer’s PARP InhibitorRead More »

PARP Inhibitors Slow Tumor Growth in 85% of Advanced Breast Cancer Patients

Editor’s Note: The following is a press release based on a recent PARP Inhibitor study/trial. We have not edited this press release in any way. The source of the press release is Penn Medicine. It is our editorial policy to always let you know when something we publish is a press release and who the …

PARP Inhibitors Slow Tumor Growth in 85% of Advanced Breast Cancer PatientsRead More »

PARP Inhibitors and Triple Negative Breast Cancer

(PARP Inhibitors Videos) This is a presentation that was given at the 2009 ASCO (American Society of Clinical Oncology) event. The lecture is about how chemotherapy combined with PARP Inhibitor BS-201 may be an effective new treatment option for triple negative breast cancer. The person speaking is Joyce OShaughnessy, MD from the Baylor-Charles A. Sammons …

PARP Inhibitors and Triple Negative Breast CancerRead More »